Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of rimegepant for acute migraine in children and adolescents
2020-003761-18Phase 3Active
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rimegepant in migraine, migraine with aura and migraine without aura, sponsored by Pfizer. Primary endpoints: On-treatment and treatment-emergent adverse events, Serious adverse events and 2 more. Started Oct 2021; status: active.
02
Drugs
rimegepant
03
Conditions
migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on 2020-003761-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003761-18.